STALICLA becomes a clinical stage company, with the approval of its STP1 investigational new drug (IND) application by the FDA
STP1 is the first precision treatment to enter the clinic for a biologically-defined subgroup of patients with autism spectrum disorder.
As soon as we proceed with full local IRB clearance, we will keep all updated on First patient dosed said Lynn Durham, Chief Executive Officer and founder of STALICLA.
In parallel, STALICLA is pursuing the advancement of observational clinical studies to enrich its first-in-class phenotype/omics biobank and accelerate its mission to bring drug development for idiopathic Autism and ill - defined NDDs to the era of precision therapeutics.
Read more:
Learn more from CCHMC Principal Investigator Craig Erickson on Precision Medicine for patients with ASD: https://youtu.be/Y7ZAp-GJtHM